Jeevan Scientific Technology Receives 'Sell' Rating

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has recently received a 'Sell' rating from MarketsMOJO on September 6, 2023. This downgrade is based on the company's poor long-term growth, with an annual operating profit growth rate of -213.67% over the last 5 years.
In addition, the company's recent results for September 2023 have been flat, indicating a lack of growth in the near future. The stock is also considered risky due to its negative operating profits and below-par performance compared to the BSE 500 index.

One positive aspect of Jeevan Scientific Technology is its strong ability to service debt, with a low Debt to EBITDA ratio of 0.86 times. However, the technical trend for the stock is currently sideways, with no clear price momentum.

It is worth noting that the majority of shareholders for Jeevan Scientific Technology are non-institutional investors. This may suggest a lack of confidence in the company's future prospects.

Overall, the downgrade to a 'Sell' rating by MarketsMOJO highlights the challenges facing Jeevan Scientific Technology in the pharmaceutical and drug industry. Investors should carefully consider these factors before making any investment decisions.